We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

21 hedge funds and large institutions have $496K invested in Agile Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

40% more capital invested

Capital invested by funds: $355K → $496K (+$141K)

24% more funds holding

Funds holding: 17 → 21 (+4)

Holders
21
Holders Change
+4
Holders Change %
+23.53%
% of All Funds
0.31%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
5
Increased
7
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$119K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$41.2K
3
AC
Armistice Capital
New York
+$20.1K
4
Citadel Advisors
Citadel Advisors
Florida
+$12.9K
5
JP Morgan Chase
JP Morgan Chase
New York
+$8.53K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$593
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$84
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2
4
Osaic Holdings
Osaic Holdings
Arizona
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$211K +$20.1K +10,000 +10%
Renaissance Technologies
2
Renaissance Technologies
New York
$115K +$119K +59,200 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$39.9K +$41.2K +20,477 New
Citadel Advisors
4
Citadel Advisors
Florida
$37.5K +$12.9K +6,422 +50%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$26.8K -$84 -42 -0.3%
State Street
6
State Street
Massachusetts
$21.1K – – –
JP Morgan Chase
7
JP Morgan Chase
New York
$15K +$8.53K +4,243 +122%
BlackRock
8
BlackRock
New York
$11.2K -$593 -295 -5%
TRCT
9
Tower Research Capital (TRC)
New York
$6.39K +$2.18K +1,085 +50%
ASN
10
Advisory Services Network
Georgia
$3.94K +$4.06K +2,020 New
IA
11
Investor AB
Sweden
$3.42K +$3.53K +1,754 New
UBS Group
12
UBS Group
Switzerland
$2.71K +$2.79K +1,387 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$2K +$1.09K +544 +214%
Citigroup
14
Citigroup
New York
$353 – – –
Morgan Stanley
15
Morgan Stanley
New York
$176 +$91 +45 +100%
Wells Fargo
16
Wells Fargo
California
$37 +$10 +5 +36%
CPG
17
Cornerstone Planning Group
New Jersey
$20 – – –
Group One Trading
18
Group One Trading
Illinois
$20 – – –
Comerica Bank
19
Comerica Bank
Texas
$8 – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$7 -$2 -1 -20%
Fidelity Investments
21
Fidelity Investments
Massachusetts
– -$2 -1 Closed

AGRX Hedge Fund Activity: Q4 2023 in Review

21 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2023, worth a combined $496K — up 40% from $355K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new AGRX positions and 1 closed out — a net gain of 4 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $119K. The largest seller was BlackRock, cutting an estimated $593.

  • 21 institutional investors held Agile Therapeutics (AGRX) as of Q4 2023, up from 17 in Q3 2023.
  • Funds reported $496K of Agile Therapeutics stock for Q4 2023, up 40% quarter-over-quarter.
  • 5 funds opened new Agile Therapeutics positions in Q4 2023 and 1 closed out, a net change of +4 holders.
  • The largest Agile Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $119K added.
  • The largest Agile Therapeutics seller in Q4 2023 was BlackRock, an estimated $593 sold.

Based on aggregated 13F filings for Q4 2023.